Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 May;52(5):602-610.
doi: 10.1007/s00535-016-1260-7. Epub 2016 Sep 17.

A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia

Kumiko Nakamura  1 , Toshihiko Tomita  1 , Tadayuki Oshima  1 , Haruki Asano  1 , Takahisa Yamasaki  1 , Takuya Okugawa  1 , Takashi Kondo  1 , Tomoaki Kono  1 , Katsuyuki Tozawa  1 , Yoshio Ohda  1 , Hirokazu Fukui  1 , Fukushima Kazuhito  2 , Shozo Hirota  2 , Jiro Watari  1 , Hiroto Miwa  3
Affiliations
Randomized Controlled Trial

A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia

Kumiko Nakamura et al. J Gastroenterol. 2017 May.

Erratum in

Abstract

Background: Acotiamide is widely used to improve symptoms in patients with functional dyspepsia (FD) in multiple large-scale clinical studies, but there are few reports about the drug's mechanism of action. The aim of this study was to assess the effects of acotiamide on gastric accommodation and gastric emptying, gastrointestinal symptoms, and health-related quality of life (HR-QOL) in a placebo-controlled study.

Methods: We conducted a randomized, double-blind placebo-controlled study. Fifty Japanese FD patients were randomly assigned to either placebo (n = 25) or acotiamide 100 mg × 3/day for 2 weeks (n = 25). At baseline and at 2 weeks of treatment, we evaluated the patients' gastric motility using scintigraphy to determine the accommodation and emptying values, gastrointestinal symptom rating scale (GSRS), HR-QOL (SF-8), and anxiety and depression scale (HADS).

Results: Four patients failed to complete the medication regimen and were omitted from analysis; data from 24 placebo patients and 22 acotiamide patients were analyzed. Acotiamide significantly increased gastric accommodation compared to the placebo (p = 0.04 vs. p = 0.08; respectively). Acotiamide significantly accelerated gastric emptying (50 % half-emptying time) (p = 0.02 vs. p = 0.59). Acotiamide significantly improved the total GSRS scores compared to placebo (p = 0.0007 vs. p = 0.14). HR-QOL did not differ significantly between the two groups, but acotiamide significantly improved the HADS anxiety score compared to placebo (p = 0.04 vs. p = 0.20).

Conclusions: Our placebo-controlled study demonstrated that acotiamide significantly increased both gastric accommodation and gastric emptying in Japanese FD patients. Acotiamide also improved the patients' dyspeptic symptoms and anxiety score. Clinical Trials Registry no: UMIN000013544.

Keywords: Acotiamide; Functional dyspepsia; Gastric motility.

PubMed Disclaimer

References

    1. Nihon Yakurigaku Zasshi. 2014 Feb;143(2):84-94 - PubMed
    1. Dig Dis Sci. 1996 Apr;41(4):689-96 - PubMed
    1. Nat Rev Gastroenterol Hepatol. 2013 Mar;10(3):134-41 - PubMed
    1. J Pharmacol Exp Ther. 2011 Mar;336(3):791-800 - PubMed
    1. J Gastroenterol. 2014 Feb;49(2):206-18 - PubMed

Publication types

MeSH terms

LinkOut - more resources